For patients with relapsed or refractory haematological malignancies, CAR-T cell therapy has been one of the most closely followed developments in recent years. Approved products are now available in Malaysia, but treatment slots, scheduling and out-of-pocket limits are the first figures most families need to work out. This article breaks down the publicly disclosed pricing structure of CAR-T products already marketed in China and how inpatient bills are settled, to help families build a verifiable cost framework before making decisions.
1. Why Malaysian patients look at CAR-T in China
- Product availability: several CAR-T therapies targeting CD19 and BCMA are approved and marketed in China, covering indications such as relapsed or refractory diffuse large B-cell lymphoma and multiple myeloma.
- Scheduling rhythm: haematology departments at public Grade 3A hospitals tend to assess and admit patients in cohorts, which differs from the case-by-case scheduling used by private institutions.
- Cost level: publicly available comparisons indicate that the total spend for a Malaysian patient completing the full pathway in China is around 25%-30% of comparable treatment in Europe and the United States, which is why most families include China in their comparisons.
2. Where the costs arise
CAR-T is not billed as a single item; it is built up from several stages. When budgeting, families are advised to check each item in the following order:
| Stage | Main cost components | Notes |
|---|---|---|
| Pre-apheresis assessment | Imaging, cardiac and organ function, infection screening | Determines whether apheresis can proceed |
| Apheresis and manufacturing | Leukapheresis, cold-chain transport, manufacturing fee | The manufacturing period depends on the hospital’s schedule |
| Bridging therapy | Transitional treatment to control disease progression | Not required for every patient |
| Lymphodepletion | Chemotherapy and supportive medication | Takes place during the inpatient stay |
| Reinfusion and monitoring | Reinfusion procedure, ICU or laminar-flow ward monitoring | Length of stay varies widely between patients |
| Post-discharge follow-up | Reviews, monitoring for infection and neurotoxicity | Usually takes several months |
The table above explains when costs arise; it is not a quotation. Actual amounts are based on the official charges issued by the hospital.
3. How to read efficacy and follow-up data
Public reports frequently cite measures such as complete response rate and objective response rate. Before reading them, it is worth confirming three things:
- What the denominator is: how many prior lines had failed in the enrolled population and whether patients with central nervous system involvement were included determine whether the data can apply to a particular patient.
- How long the follow-up was: response rates describe a snapshot at one point in time, while long-term survival depends on the length of follow-up.
- Who issued the data: whether it comes from the hospital itself or a registered clinical study disclosure, rather than a second-hand account.
YILV CHINA does not provide judgments on treatment efficacy. It helps organise medical records into a form doctors can read quickly, and the treating team gives the conclusion.
4. The full sequence from Kuala Lumpur to a hospital in China
- Medical record preparation and translation: discharge summaries, pathology reports, flow cytometry and cytogenetics results, and recent imaging (including DICOM).
- Online pre-assessment: the file is submitted to the relevant haematology department to confirm whether it warrants assessment.
- Travel to China for consultation: outpatient assessment, additional tests, and scheduling of apheresis and manufacturing.
- Inpatient treatment: lymphodepletion, reinfusion and monitoring.
- Discharge and follow-up handover: medication to take back to Malaysia, review scheduling and handover to the treating doctor in Malaysia.
5. Payment and insurance
- All charges are settled at the hospital’s official payment counter. The platform does not handle medical payments or earn any margin on drugs or procedures.
- Claim pathways differ between Malaysian medical cards, high-end direct billing policies and Takaful. It is advisable to complete a policy pre-review before travelling to China.
- An English medical report and corporate receipts are needed for claims after discharge; these documents can be requested at the time of discharge.
6. Frequently asked questions
Q: Can we have the assessment in China first and then decide whether to proceed with treatment? Yes. Assessment and treatment are two separate stages; most families complete the assessment first and then plan their trip accordingly.
Q: Can family members accompany the patient during treatment? Yes. Caregiving arrangements, accommodation and halal meals can all be coordinated.
Specific indications, contraindications and treatment decisions must be made independently by the treating physician team at the receiving hospital based on in-person examination findings. This article explains the process and cost structure and does not constitute medical advice.